Antibody Information

General Information of This Antibody
Antibody ID
ANTI0HXVAB
Antibody Name
3D1
Organization
Pfizer Inc.
Synonyms
3D1
   Click to Show/Hide
Antigen Name
Interleukin-3 receptor subunit alpha (IL3RA)
  Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLQQSGPELVKPGASVKMSCKASGYTFSDYFMKWVKQSHGKRLEWIGDINPNNGETFY
NHHFKGKATLTIDKSSSTAYMQLNSLTSDDSAVYYCARPRRGNAMDFWGQGTSVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLOSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDRTHTCPPCPAPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRELLQGST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
GNVFSCSVMHEALHNHYTQKSLSLSPG
    Click to Show/Hide
Heavy Chain Varible Domain
EVQLQQSGPELVKPGASVKMSCKASGYTFSDYFMKWVKQSHGKRLEWIGDINPNNGETFY
NHHFKGKATLTIDKSSSTAYMQLNSLTSDDSAVYYCARPRRGNAMDFWGOGTSVTVSS
    Click to Show/Hide
Heavy Chain CDR 1
GYTFSDYFMK
    Click to Show/Hide
Heavy Chain CDR 2
DINPNNGETFYNHHFKG
    Click to Show/Hide
Heavy Chain CDR 3
PRRGNAMDF
    Click to Show/Hide
Light Chain Sequence
DIVMTQSPSSLAMSVGQKVTMSCKSSQSLLNRGNQKNYLAWYQQKPGQSPKFLVYFASTR
ESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHYSIPYTFGGGTKLEIQRTVAAPS
VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
DIVMTOSPSSLAMSVGQKVTMSCKSSQSLLNRGNQKNYLAWYQQKPGQSPKFLVYFASTR
ESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHYSIPYTFGGGTKLEIQ
    Click to Show/Hide
Light Chain CDR 1
KSSOSLLNRGNQKNYLA
    Click to Show/Hide
Light Chain CDR 2
FASTRES
    Click to Show/Hide
Light Chain CDR 3
QQHYSIPYT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
JP2024177330A5 3D1-CPI [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.33 ng/mL
High CD123 expression (CD123+++)
Method Description
MOLM13 cell line cells were incubated with ADC or control at the following doses: 100 ng/ml, 25 ng/ml, 6.25 ng/ml, 1.56 ng/ml, 0.39 ng/ml, 0.09 ng/ml, 0.024 ng/ml, 0.006 ng/ml, 0.002 ng/ml and 0.0004 ng/ml. for 96 hours. Cell viability was measured with CelltiterGlo (Promega, Madison, WI), and luminescence was determined using a Victor plate reader (Perkin Elmer, Waltham, MA). 50% inhibition value (IC50) calculations were generated using XLfit (IDBS, Boston, MA) 4 parameter curve fit.

   Click to Show/Hide
In Vitro Model Adult acute myeloid leukemia MOLM-13 cells CVCL_2119
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 104.68 ng/mL Negative CD123 expression (CD123-)
Method Description
HL60 cell line cells were incubated with ADC or control at the following doses: 100 ng/ml, 25 ng/ml, 6.25 ng/ml, 1.56 ng/ml, 0.39 ng/ml, 0.09 ng/ml, 0.024 ng/ml, 0.006 ng/ml, 0.002 ng/ml and 0.0004 ng/ml. for 96 hours. Cell viability was measured with CelltiterGlo (Promega, Madison, WI), and luminescence was determined using a Victor plate reader (Perkin Elmer, Waltham, MA). 50% inhibition value (IC50) calculations were generated using XLfit (IDBS, Boston, MA) 4 parameter curve fit.

   Click to Show/Hide
In Vitro Model Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation HL60 cells CVCL_0002
References
Ref 1 JP2024177330A5 - Google Patents